I understand that of the 28 patients studied that

I understand that of the 28 patients studied that after 48 months 4 are cancer free and 1 is medically stable. What I'm seeing is that the remaining 23 patients did not survive past the 1-year, 2-year, or 3-year intervals, respectively.

Only 3 patients received the 700mg dose. Is it clear that all three are in the 48+ survival group? Fifteen patients had their dosage increased to 525mg. Are the other two 48+ month survivors in that group?

All five of the 48+ month survivors were administered at least 525 mg Leronlimab "in combination, or subsequently, with immunotherapy PD-L1 inhibitors. Is that correct?

If my math is correct, 6 patients survived past 24 months and 5 patients survived past 36 months. That was the dosage for those survivors? Isn't survival of 11 patients past 24 months also significant; if not statistically, at least personally.

After all "patients' median overall survival (mOS) have been found to be" 6.6 months, 11.8 months, and 9.9 months.with the other studied modalities. That isn't even equivalent to the 10 patients who survived past 1 year.Isn't that also significant?

Many thanks to you who have attempted to explain some very technical outcomes to guys like me interested in a micro-cap investment that also holds benefit for an unserved population.